UPDATE ON ACREAGE PHARMS LTD.
June 12 2019 - 9:15AM
INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company")
(TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) Mr. Trevor Dixon,
Chief Executive Officer of Invictus, is pleased to report that the
Phase I and II facilities of the Company’s wholly owned subsidiary
Acreage Pharms Ltd. (“
Acreage Pharms”), comprising
a total of 40,000 sq. ft of combined space, are now in full
production and is commencing the third harvest cycle from their
eleven flowering rooms. Phase II was licensed for production
under Health Canada’s Access to Cannabis for Medical Purposes
Regulations ("
ACMPR") on August 31, 2018 and is
currently harvesting four room harvests per month. Total
production has now reached over 200 kg per month of dry bud and dry
cannabis for Acreage Pharms' in-house CO2 critical gas extraction.
Phase I and II are meeting the planned production of 2,400 kg per
year. Acreage Pharms is averaging a price of $5.95 per gram sold of
dry bud.
On Behalf of the Board
Trevor Dixon
Chief Executive Officer
Investor Relations 1-844-800-6086
E-Mail: connect@invictus-md.com
Neither the TSX Venture Exchange nor its Regulation
Services Provider accepts responsibility for the adequacy or
accuracy of this release.
Kathy Love
Invictus MD Strategies Corp.
kathy@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024